Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218809 · ClinicalTrials.gov registry record · Phase 3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
A Phase 3 study of Epithelial Ovarian Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT07218809: Recruiting Phase 3 study of Epithelial Ovarian Cancer, sponsored by AstraZeneca.
NCT07218809 is a Phase 3 study of Epithelial Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,100 participants, above the 184-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (498% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218809, a Phase 3 study of Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Primary Outcome
PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause.
Conditions Studied
Interventions
- DRUG AZD5335
- DRUG Paclitaxel
- DRUG Mirvetuximab Soravtansine (MIRV)
- DRUG Pegylated liposomal Doxorubicin (PLD)
- DRUG Topotecan
Study Locations (20)
Illinois
- Research Site - Evanston
- Research Site - Peoria
- Research Site - Urbana
Other
- Research Site - Adelaide
- Research Site - Auchenflower
- Research Site - Box Hill
Florida
- Research Site - Fort Lauderdale
- Research Site - Jupiter
Massachusetts
- Research Site - Burlington
- Research Site - Worcester
Ohio
- Research Site - Dayton
- Research Site - Sylvania
Texas
- Research Site - San Antonio
- Research Site - Tyler
Maryland
- Research Site - Towson
Minnesota
- Research Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2030-05-27 |
| Phase | Phase 3 |
What NCT07218809 shows while recruiting
NCT07218809 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 184-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (498% higher).
The record links to 1 condition, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD5335 is the first listed.
NCT07218809 names 20 study sites across 12 states, led by Illinois, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07218809 about?
NCT07218809 is a clinical study titled "AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer". The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
What is the current status of trial NCT07218809?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-12-29. Estimated completion is 2030-05-27.
What conditions does trial NCT07218809 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT07218809?
The interventions under investigation include: AZD5335 (DRUG), Paclitaxel (DRUG), Mirvetuximab Soravtansine (MIRV) (DRUG), Pegylated liposomal Doxorubicin (PLD) (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT07218809?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218809 being conducted?
This trial has 20 study locations across Florida, Illinois, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218809's enrollment target sits among peer trials
1,100 2nd of 41 the highest of 41 other Epithelial Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epithelial Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
COMPLETED · Phase 3
-
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
COMPLETED · Phase 3
-
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI